Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS Nonalcoholic steatohepatitis is a leading cause of end-stage liver disease. Hepatic steatosis and lipotoxicity result in chronic necroinflammation and direct hepatocellular injury resulting in cirrhosis, end-stage liver disease and hepatocellular carcinoma. Emricasan is a pan-caspase inhibitor that inhibits excessive apoptosis and inflammation, and decreased portal pressures and improved synthetic function in mice with CCl4-induced cirrhosis. METHODS This double-blind, placebo-controlled study randomized 217 subjects with decompensated NASH cirrhosis 1:1:1 to emricasan (5 or 25 mg) or placebo. Patients were stratified by decompensation status and baseline MELD-Na score. The primary endpoint was comprised of any subject who died, had a new decompensation event (new or recurrent variceal hemorrhage, new ascites requiring diuretics, new unprecipitated hepatic encephalopathy ≥ grade 2, hepatorenal syndrome, spontaneous bacterial peritonitis), or an increase in MELD-Na score ≥4 points. RESULTS There was no difference in event rates between either of the emricasan treatment groups and placebo, with hazard ratios of 1.02 (5 mg; 95% confidence interval 0.59, 1.77; p=0.94) and 1.28 (25 mg; 95% confidence interval 0.75, 2.21; p=0.37). MELD-Na score progression was the most common outcome. There was no significant effect of emricasan treatment on MELD-Na score, INR, total serum bilirubin albumin level or Child-Turcotte-Pugh score. Emricasan was generally safe and well-tolerated. CONCLUSIONS Emricasan was safe but ineffective in treatment of decompensated NASH cirrhosis with regard to MELD-Na score improvement, reducing new decompensation events, improving liver function or mortality. However, this study may guide the design and conduct of future clinical trials in decompensated NASH cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S., Shiffman, M. L., Aguilar Schall, R., Jia, C., McColgan, B., et al. (2019) · Hepatology · doi:10.1002/hep.30664 · Cited by 390
Self-citationReport on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
Rinella, M. E., Tacke, F., Sanyal, A. J., & Anstee, Q. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.019 · Cited by 209
Self-citation
Cited by
Mitochondria and cell death-associated inflammation
Vringer, E., & Tait, S. W. G. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-022-01094-w · Cited by 431
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01439-y · Cited by 272
Frankowski, R., Kobierecki, M., Wittczak, A., Różycka-Kosmalska, M., Pietras, T., Sipowicz, K., & Kosmalski, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119677 · Cited by 58
Metadata
- Authors
- Frenette, C., Kayali, Z., Mena, E., Mantry, P. S., Lucas, K. J., Neff, G., Rodriguez, M., Thuluvath, P. J., Weinberg, E., Bhandari, B. R., Robinson, J., Wedick, N., Chan, J. L., Hagerty, D. T., Kowdley, K. V., Corey, K., Bernstein, D., Noureddin, M., Kemmer, N., DeLemos, A., Pyrsopoulos, N., Lee, W., Ghabril, M., Scanga, A., McKenzie, M., Lawitz, E., Figueroa-Diaz, V., Simonetto, D., Frederick, R., Brown, K., Therapondos, G., Sheikh, A., Brandman, D., Stein, L., Ankoma-Sey, V., Bhamidimarri, K., Landis, C., Fortune, B., Vargas, H., Abdelmalek, M., Freilich, B., Rockey, D., Vierling, J., Tatum, H., Curry, M., Shiffman, M., Bambha, K., Ghalib, R., Stratton, A., Anwar, N., Caldwell, S., Koteish, A., Siddiqui, M., Saab, S., Shah, N., Kohli, A., Rinella, M., Sarkar, S., Torres, D., Verna, E., Ravendhran, R., Reynolds, J., Thomason, R., Kim, R., Membreno, F., Jakab, S., Gonzalez, S., Keaveny, A., Pan, J.-J., Gill, S., Huang, J., Strobel, J., Wieland, A., Morelli, G., Amankonah, T., Roytman, M., Schmidt, W., Abrams, G., & Patel, B.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 74
- Issue
- 2
- Pages
- 274-282
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3092528327
- Cited by
- 62
- References
- 4
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. https://app.cochat.ai/papers/10.1016/j.jhep.2020.09.029
- The paper
- Frenette, C., Kayali, Z., Mena, E., Mantry, P. S., Lucas, K. J., Neff, G., Rodriguez, M., Thuluvath, P. J., Weinberg, E., Bhandari, B. R., Robinson, J., Wedick, N., Chan, J. L., Hagerty, D. T., Kowdley, K. V., Corey, K., Bernstein, D., Noureddin, M., Kemmer, N., . . . Patel, B. (2021). Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.09.029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.